Standards of Care in Diabetes 2026 Update for Early Career Professionals | Recording-Standards of Care in Diabetes 2026 Update for Early Career Professionals

Video Transcription

Video Summary

This ADA Scholars Program webinar for early-career clinicians previewed key elements of the ADA Standards of Care in Diabetes—2026. The Standards are updated annually via systematic literature review, graded evidence (A–E), independent funding (no industry support), and “living” updates as new data emerge.<br /><br />Major updates included: expanded guidance on screening for presymptomatic type 1 diabetes using islet autoantibodies (insulin, GAD, IA-2, ZnT8), follow-up metabolic staging, and referral for potential disease-modifying therapy (teplizumab) in stage 2 disease. New content addressed diabetes risk and management with cancer therapies (e.g., glucocorticoids, immune therapies, PI3K/mTOR inhibitors), including considering metformin to prevent hyperglycemia in high-risk patients.<br /><br />Other highlights: stronger focus on health equity, social determinants, and DSMES; updated nutrition and psychosocial screening (including vaping); individualized glycemic goals incorporating CGM metrics plus sick-day guidance; broader support for early CGM and automated insulin delivery without C-peptide/antibody prerequisites; new obesity guidance in type 1 diabetes; updated type 2 pharmacotherapy algorithms prioritizing ASCVD, heart failure, CKD, weight, and hypoglycemia avoidance; and expanded BP/CKD recommendations (lower BP targets when safe, wider finerenone use, continued SGLT2i in advanced CKD). Sections also emphasized foot-care technologies, older-adult frameworks, and pediatric updates including newer agents for youth type 2 diabetes.

Keywords

ADA Standards of Care in Diabetes 2026

ADA Scholars Program webinar

presymptomatic type 1 diabetes screening

islet autoantibodies (GAD, IA-2, ZnT8)

teplizumab stage 2 type 1 diabetes

continuous glucose monitoring (CGM) metrics

automated insulin delivery (AID)

type 2 diabetes pharmacotherapy algorithm (ASCVD, HF, CKD)

SGLT2 inhibitors and finerenone in CKD